MedPath

INDIVIOR INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

53

Active:3
Completed:46

Trial Phases

4 Phases

Phase 1:15
Phase 2:12
Phase 3:5
+1 more phases

Drug Approvals

4

FDA:4

Drug Approvals

Suboxone

Approval Date
Dec 18, 2023
FDA

SUBLOCADE

Approval Date
Dec 18, 2023
FDA

OPVEE

Approval Date
Nov 20, 2023
FDA

PERSERIS

Approval Date
Aug 15, 2023
FDA

Clinical Trials

Distribution across different clinical trial phases (44 trials with phase data)• Click on a phase to view related trials

Phase 1
15 (34.1%)
Phase 2
12 (27.3%)
Phase 4
12 (27.3%)
Phase 3
5 (11.4%)

INDV-6001 Multiple-Dose Pharmacokinetic Study

Phase 2
Recruiting
Conditions
Moderate to Severe Opioid Use Disorder
Interventions
First Posted Date
2024-08-29
Last Posted Date
2025-07-01
Lead Sponsor
Indivior Inc.
Target Recruit Count
122
Registration Number
NCT06576843
Locations
🇺🇸

Artemis Institute for Clinical Research, San Diego, California, United States

🇺🇸

Innovative Clinical Research, Inc., Miami Lakes, Florida, United States

🇺🇸

Chicago Clinical Research Institute Inc., Chicago, Illinois, United States

and more 8 locations

Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Phase 2
Active, not recruiting
Conditions
Opioid Use Disorder
Interventions
Other: Placebo
First Posted Date
2024-04-25
Last Posted Date
2025-07-15
Lead Sponsor
Indivior Inc.
Target Recruit Count
300
Registration Number
NCT06384157
Locations
🇺🇸

Boyett Health Services Inc, Hamilton, Alabama, United States

🇺🇸

Elite Clinical Studies, LLC, Phoenix, Arizona, United States

🇺🇸

North County Clinical Research, Oceanside, California, United States

and more 32 locations

Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants

Phase 1
Completed
Conditions
Opioid Use Disorder
Interventions
First Posted Date
2023-08-03
Last Posted Date
2025-02-13
Lead Sponsor
Indivior Inc.
Target Recruit Count
7
Registration Number
NCT05974046
Locations
🇺🇸

Celerion, Lincoln, Nebraska, United States

Evaluating the SUBLOCADE Treatment Exit Strategy

Completed
Conditions
Opioid Use Disorder
First Posted Date
2023-05-26
Last Posted Date
2025-06-04
Lead Sponsor
Indivior Inc.
Target Recruit Count
12
Registration Number
NCT05878210
Locations
🇺🇸

Comprehensive Addiction Medicine, Portland, Maine, United States

🇨🇦

Savera Medical Centre, Edmonton, Alberta, Canada

SUBLOCADE Long-term Outcomes

Active, not recruiting
Conditions
Opioid Use Disorder
First Posted Date
2023-05-16
Last Posted Date
2025-07-04
Lead Sponsor
Indivior Inc.
Target Recruit Count
1200
Registration Number
NCT05860959
Locations
🇺🇸

ATP Clinical Research, Costa Mesa, California, United States

🇺🇸

Neighborhood Healthcare-Institute of Health, Escondido, California, United States

🇺🇸

Elevate Health and Wellness, Westport, Connecticut, United States

and more 46 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 11
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.